Wolfgang Miesbach: From CD20 to CD38 – A New Dimension in ITTP Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Paul Coppo, published in JTH, adding։
“From CD20 to CD38: a new dimension in iTTP therapy.
Preemptive rituximab guided by ADAMTS13 has transformed iTTP follow-up, but a subset of patients still relapse or remain refractory and need alternative strategies.
In a recent RPTH commentary, Paul Coppo highlights daratumumab in 5 heavily pretreated iTTP patients (8 episodes), with an 87.5% overall response rate, rapid ADAMTS13 recovery in about 2–4 weeks, and a median ADAMTS13 relapse-free survival of 32 months, without reported infectious complications.
By targeting CD38 on long-lived plasma cells, daratumumab depletes persistent anti–ADAMTS13–producing cells that are not eliminated by CD20-directed therapies, offering a mechanistically distinct salvage approach in multiresistant iTTP.”
Title: Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy
Author: Paul Coppo
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026